ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Image-guided high-dose-rate brachytherapy after short-course external beam radiotherapy for elderly/frail rectal cancer patients.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFor elderly and frail patients with rectal cancer, unfit for radical surgery or extensive chemoradiation schedules, radiotherapy dose escalation by use of high-dose-rate brachytherapy (HDR-BT) may be an alternative organ-preserving approach.
methods15 elderly/frail patients (median age, 83 years; ECOG 1‑2: 80%) with histologically confirmed rectal adenocarcinoma (T1-3, N0-1, M0; UICC stage I-IIIB) were treated with definitive radiotherapy consisting of external beam radiation therapy (EBRT) of 30-39 Gy in 10-13 fractions, followed by image-guided endorectal HDR-BT with 12-24 Gy in 2-3 fractions. Acute and late toxicity of combined EBRT and HDR-BT was recorded according to CTCAE v5.0. Initial tumor response (clinical complete response, cCR, near clinical complete response, ncCR, and incomplete response, IR) and long-term disease control were assessed using clinical examination, endoscopy, and magnetic resonance imaging.
resultsMedian follow-up was 21 (range, 9-43) months. Six weeks after completion of EBRT + HDR-BT, cCR (n = 6) or ncCR (n = 6) was confirmed in 12/15 patients (80%), 3 patients (20%) had IR. Local regrowth after initial (n)cCR was observed in 4 patients (33%). A total of 4/15 patients (27%) developed distant metastases (2 with IR, 2 with (n)cCR). Most common acute toxicities were mild/moderate proctitis (grade 1-2) in 67%, and mild grade 2 cystitis in 27%. Three patients (20%), of whom two were receiving oral anticoagulation, experienced late grade 3 rectal bleeding, requiring blood transfusion. One patient developed grade 3 rectal ulcer with necrosis treated with rectal amputation.
conclusionsHDR-BT dose escalation after initial EBRT represents a feasible non-operative treatment option for patients unfit for surgery with promising long-term local control. The incidence of late grade 3 rectal bleeding, especially in patients receiving concomitant oral anticoagulation, requires careful patient selection, and further dose and treatment optimization (as implemented in the upcoming ACO/ARO/AIO-22 trial).
Indexed as
Identifiers
42734824What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.